Loading...
Kura Oncology Community
NasdaqGS:KURA Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
Community Investing Ideas
Upcoming FDA Approval Will Open New Oncology Avenues
Key Takeaways Anticipated drug approvals and a diverse pipeline in high-need oncology segments set the stage for accelerated revenue growth and market expansion. Strategic partnerships and industry trends support strong financial positioning, reduced risk, and sustainable long-term earnings potential.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$31.8
62.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
61% p.a.
Profit Margin
16.98%
Future PE
56.51x
Price in 2028
US$38.74
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
Key Takeaways Ziftomenib's potential best-in-class profile and streamlined trial strategy could drive rapid adoption and transform revenue and margin growth in AML. Expanding into solid tumors and chronic diseases diversifies revenue opportunities and positions Kura as a platform company with strong long-term growth prospects.Read more
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$40
70.0% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
161% p.a.
Profit Margin
21.85%
Future PE
16x
Price in 2028
US$48.54
